Cellectis S.A. American Depositary Shares

Allogene Therapeutics won an arbitration against Cellectis regarding CAR-T therapy development rights, securing full control of cemacabtagene ansegedleucel in the U.S., EU, and U.K., while the tribunal rejected Cellectis's financial claims and allegations.

Allogene Therapeutics won a favorable arbitration ruling with Cellectis, reconfirming full development and commercial control of cemacabtagene ansegedleucel (cema-cel) in the US, EU, and UK, with a path to acquire full global rights by 2026.

Cellectis (CLLS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Penny stocks to watch this week. The post 5 Most Active Penny Stocks Today & Why They’re Moving Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Baillie Gifford’s 13F portfolio value decreased from ~$96.99B to ~$95.96B this quarter. Click here for a detailed analysis.